NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advancing Clinical Development of its Novel Advanced Breast Cancer Treatment
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is continuing its progression of Bria-IMT for the treatment of advanced breast cancer. An article discussing the company reads, “The Bria-IMT phase I/IIa monotherapy study involved 23 patients who were very heavily pre-treated (a median of four previous systemic therapy regiments per patient). The treatment with Bria-IMT was well-tolerated, with minor local irritation at the injection site being reported as the most common adverse effect. … More importantly, Bria-IMT contributed to tumor shrinkage in three of the patients. The top respondent previously received seven rounds of chemotherapy and had…